Impax Laboratories Inc. et al v. Lannett Holdings Inc. et al
Impax Laboratories Inc. and AstraZeneca AB |
Lannett Holdings Inc. and Lannett Company Inc. |
1:2014cv00984 |
July 25, 2014 |
US District Court for the District of Delaware |
Wilmington Office |
New Castle |
Leonard P. Stark |
Patent |
35 U.S.C. ยง 271 |
None |
Available Case Documents
The following documents for this case are available for you to view or download:
Document Text |
---|
Filing 169 TRIAL OPINION. Defendants have failed to prove the Dearn patents are invalid. If desired, Defendants should request an opportunity to cross-examine Ms. Allen within one week. If Defendants do not make that request, the parties should submit an agreed upon form of final judgment within two weeks. Signed by Judge Richard G. Andrews on 3/29/2017. (nms) |
Filing 60 MEMORANDUM OPINION providing claim construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties shall submit a proposed order consistent with this Memorandum Opinion. Signed by Judge Richard G. Andrews on 12/1/2015. (nms) |
Filing 33 MEMORANDUM ORDER Consolidating Cases and Denying Motion to Dismiss (see D.I. 9 in 14cv984-RGA). Signed by Judge Richard G. Andrews on 12/10/2014. Associated Cases: 1:14-cv-00984-RGA, 1:14-cv-00999-RGA(nms) |
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.